Gilead Sciences, Inc. (NASDAQ:GILD) Shares Sold by First Financial Bank Trust Division

First Financial Bank Trust Division cut its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 39.8% during the first quarter, HoldingsChannel.com reports. The firm owned 93,309 shares of the biopharmaceutical company’s stock after selling 61,762 shares during the period. First Financial Bank Trust Division’s holdings in Gilead Sciences were worth $6,835,000 at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. Tompkins Financial Corp grew its stake in Gilead Sciences by 223.1% in the 3rd quarter. Tompkins Financial Corp now owns 349 shares of the biopharmaceutical company’s stock valued at $26,000 after acquiring an additional 241 shares during the last quarter. Fortitude Family Office LLC acquired a new stake in Gilead Sciences in the 4th quarter valued at about $29,000. Private Wealth Management Group LLC acquired a new stake in Gilead Sciences in the 4th quarter valued at about $29,000. Sachetta LLC acquired a new stake in Gilead Sciences in the 4th quarter valued at about $30,000. Finally, Rakuten Securities Inc. acquired a new stake in Gilead Sciences in the 4th quarter valued at about $33,000. 83.67% of the stock is owned by institutional investors and hedge funds.

Gilead Sciences Trading Down 1.8 %

NASDAQ GILD traded down $1.14 during mid-day trading on Tuesday, hitting $63.13. The company’s stock had a trading volume of 1,714,608 shares, compared to its average volume of 7,221,358. Gilead Sciences, Inc. has a 52-week low of $62.07 and a 52-week high of $87.86. The stock’s fifty day simple moving average is $65.92 and its two-hundred day simple moving average is $73.23. The company has a debt-to-equity ratio of 1.31, a current ratio of 1.08 and a quick ratio of 0.94. The firm has a market capitalization of $78.65 billion, a P/E ratio of 178.53, a price-to-earnings-growth ratio of 1.30 and a beta of 0.20.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Thursday, April 25th. The biopharmaceutical company reported ($1.32) EPS for the quarter, beating the consensus estimate of ($1.49) by $0.17. Gilead Sciences had a net margin of 1.76% and a return on equity of 24.34%. The firm had revenue of $6.69 billion for the quarter, compared to analyst estimates of $6.36 billion. During the same quarter last year, the firm posted $1.37 earnings per share. Gilead Sciences’s revenue for the quarter was up 5.3% compared to the same quarter last year. Research analysts expect that Gilead Sciences, Inc. will post 3.75 EPS for the current year.

Gilead Sciences Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, June 27th. Investors of record on Friday, June 14th will be issued a $0.77 dividend. The ex-dividend date of this dividend is Friday, June 14th. This represents a $3.08 annualized dividend and a yield of 4.88%. Gilead Sciences’s payout ratio is 855.56%.

Insider Activity at Gilead Sciences

In other Gilead Sciences news, insider Merdad Parsey sold 2,000 shares of the stock in a transaction that occurred on Monday, April 1st. The shares were sold at an average price of $72.96, for a total value of $145,920.00. Following the completion of the sale, the insider now owns 96,304 shares of the company’s stock, valued at $7,026,339.84. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.29% of the stock is currently owned by insiders.

Analysts Set New Price Targets

GILD has been the topic of a number of research reports. Mizuho lowered their price objective on shares of Gilead Sciences from $101.00 to $90.00 and set a “buy” rating on the stock in a research note on Thursday, February 22nd. TD Cowen reduced their target price on shares of Gilead Sciences from $90.00 to $85.00 and set a “buy” rating on the stock in a report on Friday, April 26th. UBS Group reduced their target price on shares of Gilead Sciences from $81.00 to $75.00 and set a “neutral” rating on the stock in a report on Wednesday, April 17th. Truist Financial lowered shares of Gilead Sciences from a “buy” rating to a “hold” rating and reduced their target price for the company from $91.00 to $82.00 in a report on Thursday, February 22nd. Finally, StockNews.com upgraded shares of Gilead Sciences from a “buy” rating to a “strong-buy” rating in a report on Saturday, April 27th. Eleven research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $83.69.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.